← Eichor
Study identifier: NCT03630991 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Condition: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants58
Who can joinAll sexes, 1 Year to no upper limit
Healthy volunteersNo

About this study

This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Maro Ohanian  ·  713-792-2631  ·  mohanian@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

M D Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03630991